|
TAF2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.56541446472147E-14 |
| Normal-vs-Stage2 |
1.72680003629466E-09 |
| Normal-vs-Stage3 |
7.56061879769732E-14 |
| Normal-vs-Stage4 |
3.41515704604944E-12 |
| Stage1-vs-Stage2 |
5.521800E-01 |
| Stage1-vs-Stage3 |
7.653800E-02 |
| Stage1-vs-Stage4 |
5.186400E-02 |
| Stage2-vs-Stage3 |
5.163800E-01 |
| Stage2-vs-Stage4 |
2.862400E-01 |
| Stage3-vs-Stage4 |
6.134400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
5.69129999999918E-05 |
| Normal-vs-Asian |
1.37030053970477E-10 |
| Caucasian-vs-AfricanAmerican |
3.197200E-01 |
| Caucasian-vs-Asian |
6.137400E-01 |
| AfricanAmerican-vs-Asian |
2.140000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.22044604925031E-16 |
| Normal-vs-Female |
1.62636570877339E-12 |
| Male-vs-Female |
8.952200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.57365265052567E-12 |
| Normal-vs-Age(41-60Yrs) |
4.44089209850063E-16 |
| Normal-vs-Age(61-80Yrs) |
1.80855330711438E-12 |
| Normal-vs-Age(81-100Yrs) |
1.681230E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.575800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.018400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.414800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.034600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.836400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.755400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.712500E-02 |
| Classical-VS-Follicular |
3.329400E-01 |
| Classical-VS-Other |
1.758640E-01 |
| Classical-VS-Normal |
1.63646873829748E-12 |
| Tall-VS-Follicular |
3.876400E-01 |
| Tall-VS-Other |
5.931000E-01 |
| Tall-VS-Normal |
2.01159999768663E-09 |
| Follicular-VS-Other |
3.634200E-01 |
| Follicular-VS-Normal |
8.88149553901485E-11 |
| Other-VS-Normal |
1.358960E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.33066907387547E-16 |
| Normal-vs-N1 |
1.69990022058641E-10 |
| N0-vs-N1 |
6.711400E-01 |
|
|
